Learn more about all the progress happening with Convergence and the OKC Innovation District during the Chamber's July Forum at Vast July 20.
OU Health Stephenson Cancer Center has announced a historic first for the campus and the state: A new cancer drug, called OK-1, which was conceived and created by an OU College of Medicine researcher and developed entirely in Oklahoma, without the support of a pharmaceutical company, is being tested in humans for the first time in a Phase 1 clinical trial.
Oklahoma City recently got a quick visit from a high-ranking EDA official on mission to find out more about a regional plan to expand the region’s bioscience industry. The visit was made in response to a $500,000 planning grant the EDA awarded OKC last fall as part of its Build Back Better Regional Challenge grant competition.
The Greater Oklahoma City Chamber’s annual State of Health event is about a week away, but that does not mean you won’t be able to attend this informative, worthwhile event. Tickets are still available.
Oklahoma City has steadily – and intentionally – transformed itself into an emerging bioscience and biotechnology player over the last few decades, garnering attention from across the nation and globe.
Editor's note 5-10-22: Stephanie Wierwille, SVP, Integrated Marketing at Revive, is now set to keynote State of Health and will be presenting "Joe Public 2030: Five Potent Predictions Reshaping How Consumers Engage Healthcare."
The National Institutes of Health has selected the Oklahoma Medical Research Foundation to lead a nationwide public-private partnership aimed at developing more effective treatments for autoimmune diseases.
In the rearview are days when Oklahoma City’s key sectors – academia, aerospace, bioscience, energy, healthcare, manufacturing and research – worked solely in silos, and on the road ahead lie opportunities for those industries to cross, merge and collaborate, giving the city a future at becoming a stable, international competitor in the ever-changing global economy.
